TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) is now available.
Hemogenyx Pharmaceuticals has announced the publication of a Prospectus related to the admission of new ordinary shares to the London Stock Exchange. This move involves the conversion of convertible loan notes and the exercise of warrants, with trading expected to commence on 24 November 2025. This development is significant for Hemogenyx as it enhances their market presence and potentially impacts their financial standing by increasing the number of shares available for trading.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded clinical stage biopharmaceutical company headquartered in London, with US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing a platform technology for novel product development.
Average Trading Volume: 122,583
Technical Sentiment Signal: Buy
Current Market Cap: £47.39M
Find detailed analytics on HEMO stock on TipRanks’ Stock Analysis page.